mike:

I'll give this piece my clumsy interpetation.

It appears that they found a private buyer(s)(venture capitalists) to raise about $900,000 to conduct further studies and what not. Doesn't sound like they brokered through someplace like Merrill-Lynch, but the stock is publically traded.

This is a very tiny company since it has only raised $900,000. In fact, I didn't even see this stock listed in The Wall Street Journal. I don't think they bother listing small, speculative, risky companies with stock prices that are only 16 cents per share.

The last paragraph about forward-looking statements is a nice way of saying this is a very risky stock. But, buying a lottery ticket is risky and some people actually win.

I'm not a financial analyst, so take what I say with caution, but that's how I read this.

For those just checking in, this company is trying to develop a cream (SLO17) that is applied to the skin and then an IPL is added to the mix to permanently remove any color of hair. It may not be necessary for the hair to be in the growth phase, but I'm not 100% sure about that. I need to re-check that.

Keep the faith, oh hairy brothers and sisters!

Dee

Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
EDMONTON, Dec. 17 /CNW/ - Quest PharmaTech Inc. (TSX Venture Exchange:
QPT) today announced that it has signed an agreement with a multinational
technology development company (the "Investor") to receive $3,000,000 to
develop oncology products based on its SonoLight Technology. Under the terms
of the agreement, Quest Pharma Tech Inc. ("Quest" or the "Company") has
already received $1,000,000; and the balance of $2,000,000 will be paid within
the next twelve months. In return for this non-equity funding, the Investor
who requested to remain anonymous, will receive 35 percent of all future net
revenue from the commercialization of Quest's oncology products. This
agreement does not preclude Quest from out-licensing the oncology applications
of SonoLight Technology to a third party.
The Company's lead oncology product from the SonoLight platform, SL052,
is anticipated to enter a Phase I clinical trial for photodynamic therapy
treatment of prostate cancer during the second half of 2008. The Company is
also evaluating the same technology for the treatment of lung cancer and
peritoneal carcinomatosis.
"I can't think of a better holiday present to our shareholders than
establishing an accelerated oncology development program," said Dr. Madi R.
Madiyalakan, Chief Executive Officer of Quest Pharma Tech Inc. "We are
optimistic about the potential of both our oncology products and our
dermatology program. Additionally, we believe that our partnerships with
Paramount BioSciences and KMH Co. Ltd. will help us achieve our long-term
growth objectives, including share price appreciation."

About Quest PharmaTech Inc.

The Corporation is a publicly traded (TSX Venture Exchange: QPT),
Alberta-based pharmaceutical company committed to build shareholder value
through discovery, development, and commercialization of new pharmaceutical
products. It is developing a series of products for the treatment of cancer
and dermatological conditions based on its proprietary photodynamic and
sonodynamic therapy platform. The Company's lead product, SL017, is a topical
formulation that is currently undergoing a 90 patient clinical trial in Canada
for hair removal applications. Quest has signed an exclusive multinational
license agreement with Paramount Biosciences, a global pharmaceutical and
healthcare investment firm, to develop and market SL017 for dermatology
applications. In addition, Quest also has an agreement with KMH Co. Ltd, a
Korean pharmaceutical company, to market SL017 in Asia for hair removal
applications.

Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process, and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.

"TSX Venture Exchange has neither approved nor disapproved of the
information contained herein."

%SEDAR: 00008400E


For further information: Dr. Madi R.Madiyalakan, Chief Executive
Officer, Quest Pharma Tech Inc., Tel.: (780) 448-1400 (Ext. 204),
madi@questpharmatech.com. Further information about Quest Pharma Tech Inc. can
be found at: http://www.questpharmatech.com

"The last paragraph about forward-looking statements is a nice way of saying this is a very risky stock. But, buying a lottery ticket is risky and some people actually win."

All companies use this disclaimer regardless of the risk.

taken from the webpage:

"Based on the results of the Phase I study, Quest initiated a 90 patient Phase II clinical trial in Q1, 2007 to study the combination of SL017 topical gel with Intense Pulsed Light (IPL) for hair removal. The results are anticipated in the first half of 2008."

i wish u all a happy new year!

From their homepage:

The Company's lead product, SL017, is a topical formulation that is
currently undergoing a 90 patient clinical trial in Canada for hair removal
applications, with the final report anticipated by the end of this year

Quest PharmaTech announces 2008 financial and operational results
EDMONTON, May 15 /CNW/ - Quest PharmaTech Inc. ("Quest" or the "Company")
announces the highlights of financial and operational results for the fiscal
year ended January 31, 2008.

<<
- Raised $3,128,000 in equity financings
- Received $1,316,575 in licensing fees; and $52,422 in government
grants
- Completed the Phase I clinical trial for Actinic Keratosis (final
results are due in June, 2008)
- Received Proof of concept data from Cross Cancer Institute for
prostate cancer photodynamic therapy product.
>>

Net consolidated loss for the year was $1,318,446 or $0.02 per share as
compared to a consolidated loss of $1,454,077 or $0.03 per share for the year
ended January 31, 2007. Research and development expenditures totaled $901,530
while general and administrative expenses were $869,593 for the same period.
As of January 31, 2008, the Company had cash and cash equivalents of
$1,305,802. The Company also has debt of $500,000 in the form of a convertible
debenture (exercisable at $0.25 and due on March 22, 2009).
On a forward going basis, the Company anticipates to receive $2,000,000
in licensing fees to develop oncology products based on its SonoLight
Technology. The Company may receive an additional $1,000,000 equity investment
from KMH Co., Ltd. upon reaching specific milestones related to SL017 for hair
removal applications. The Company also expects to receive up to $200,000 in
government grants to offset the costs to develop its ultrasound activation
technology.
Currently, the Company has 4,800,000 outstanding share purchase warrants
exercisable at $ 0.20 and expiring in September, 2008. If exercised, these
warrants would generate up to $960,000 of additional funding for the Company.
"I am pleased with the improved financial position of the Company that
helps us accomplish our long term business objectives", said Mr. Pierre
Vermette, Chief Financial Officer for the Company.
The Company's lead product, SL017, is a topical formulation that is
currently undergoing a 90 patient clinical trial in Canada for hair removal
applications, with the final report anticipated by the end of this year. The
Company's second product, SL052, is scheduled to enter a Phase I clinical
trial for the treatment of prostate cancer during the second half of 2008. The
Company believes it has sufficient cash to complete the 90 patient hair
removal trial, and to initiate a fifteen patient, multi centre, Phase I
clinical trial for prostate cancer treatment.
Quest has signed an exclusive multinational license agreement with
Paramount Biosciences, a global pharmaceutical and healthcare investment firm,
to develop and market SL017 for dermatology applications. In return Quest will
receive potential future milestone payments in excess of $35 million USD, plus
royalties on product sales. In addition, Quest also has an arrangement with
KMH Co., Ltd., a Korean pharmaceutical company, to market SL017 in Asia for
hair removal applications. The company also has an agreement with a
multinational technology development company to receive $3,000,000 against
future revenue to develop oncology products.

About Quest PharmaTech Inc.

The Corporation is a publicly traded (TSX Venture Exchange: QPT),
Alberta-based pharmaceutical company committed to build shareholder value
through discovery, development and commercialization of new pharmaceutical
products. It is developing a series of products for the treatment of cancer
and dermatological conditions based on its unique photodynamic and sonodynamic
therapy platform. Additional information related to the Company, including the
Company's financial statements, and management discussion and analysis, is on
SEDAR at www.sedar.com.

"TSX Venture Exchange has neither approved nor disapproved of the
information contained herein"

%SEDAR: 00008400E


For further information: Pierre Vermette, Chief Financial Officer, Tel.:
(780) 448-1400 (Ext. 217), pierre@questpharmatech.com; Dr. Madi R.Madiyalakan,
Chief Executive Officer, Tel.: (780) 448-1400 (Ext. 204),
madi@questpharmatech.com; Web site: www.questpharmatech.com
Index of Releases

Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
TSX Venture: QPT

EDMONTON, June 25 /CNW/ - Quest PharmaTech Inc. (TSX-V: QPT), ("Quest" or
the "Company"), today announced interim results from its Phase I/II clinical
study designed to investigate appropriate treatment parameters for the
potential use of its proprietary compound SL017 for hair removal applications.
The interim results represent data from the first 80 patients enrolled in the
targeted 100-patient clinical trial.
"The Phase I/II interim results demonstrated that SL017 is safe and well
tolerated when used either alone or in combination with photo activation,"
said Madi Madiyalakan, Chief Executive Officer of Quest. "These results, along
with results from the previous clinical trial, support the utility of SL017
for hair removal applications, especially for those who do not benefit from
light treatment alone."
To permanently remove unwanted hair, existing laser hair removal
techniques require four to eight treatments, and provide only a 75 to 85
percent permanent hair reduction in a limited patient population. The
professional laser hair removal market is estimated to be $5 billion
worldwide.
Quest is developing SL017 photodynamic therapy (PDT) as a potential hair
removal solution that is effective across a broad patient population including
those with light colored hair (for example, grey or blonde hair). In a Phase I
clinical trial, Quest demonstrated the preferential localization of SL017 in
hair follicles, which suggested that cutaneous PDT with SL017 has potential
for permanent hair removal applications.
The Phase I/II trial of SL017 was designed to evaluate the effect of skin
treatment on follicular uptake of SL017, assess the tolerable light dose on
healthy subjects, and subsequently, determine the efficacy of hair removal
under optimal treatment conditions. Results from this study will be used to
guide the design of future clinical development.

Skin Pretreatment and Follicular Uptake

Thirty healthy subjects were enrolled to evaluate the efficacy of five
different skin preparation techniques to enhance the follicular localization
of SL017. One of the five skin pretreatments demonstrated a statistically
significant improvement in both the intensity of follicular uptake of SL017
and the depth of penetration of SL017 in the hair follicle compared to the
other skin pretreatments.

Light Dose Escalation

Forty subjects with dark colored hair and 10 subjects with light colored
hair were enrolled to evaluate the safety and efficacy of combining SL017 with
increasing doses of Intense Pulse Light (IPL) ranging from 4.5J/cm(2) to
20.0J/cm(2). No skin pretreatment technique was used. No unexpected side
effects were observed at any of the light doses tested. A hair count was taken
at days 0 and 42 in each population. There was no statistically significant
improvement in hair count reduction observed in the subjects treated with
SL017 PDT compared to IPL treatment alone at any of the IPL doses or in either
of the two hair populations studied. However, 25% of the dark colored hair
population, or 10 subjects, that were non-responsive to IPL treatment
demonstrated a statistically significant reduction in hair count when treated
with SL017 PDT.

Hair Removal Efficacy Under Optimal Conditions

Quest is currently enrolling 20 additional patients, 10 with dark colored
hair and 10 with light colored hair, to evaluate the efficacy of SL017 PDT
compared to IPL at the optimal light dose and after skin pretreatment. The 20
subjects with light colored hair enrolled in the trial will also undergo two
SL017 PDT treatments. The hair growth of these patients will be monitored for
up to six months. Results from this part of the study are anticipated by end
of 2008.
"Based on the results we receive from these clinical studies in hair
removal and the preclinical work we are currently conducting for the treatment
of acne, we intend to advance SL017 PDT for one or more clinical indications,"
stated Thomas Woo, M.Sc., Vice President for Drug Development of Quest.
The Principal Investigator for Quest's Phase I/II hair removal trial is
Dr. Robert Bissonnette, M.D., President of Innovaderm Research in Montreal.

About SL017: SL017 is a proprietary, non-toxic drug that, once applied to
a target area and activated by light, is transformed into a potent cytotoxic
agent that selectively destroys targeted tissue. Using this process, known as
photodynamic therapy (PDT), SL017 can be applied to treat a variety of skin
conditions, including hair removal, actinic keratosis and acne. The safety and
potential utility of SL017 for the treatment of actinic keratosis has been
demonstrated in a Phase I Clinical Study.

About Quest PharmaTech Inc.: Quest is a publicly traded, Alberta-based
pharmaceutical company committed to the development and commercialization of
new pharmaceutical products. It is developing a series of products for the
treatment of cancer and dermatological conditions based on its unique
photodynamic and sonodynamic therapy platform.

"TSX Venture Exchange has neither approved nor disapproved of the
information herein."

%SEDAR: 00008400E


For further information: Dr. Madi R. Madiyalakan, Chief Executive
Officer, Quest PharmaTech Inc., Tel: (780) 448-1400 Ext. 204, Email:
madi@questpharmatech.com, Internet: www.questpharmatech.com; Investor
Relations - Adam Peeler, The Equicom Group Inc., Tel: (416) 815-0700 Ext. 225,
E-mail: apeeler@equicomgroup.com

Interesting, I wonder how effective this will be?

So when will this now be available? How much longer for Phase I/II test?

any updates on this product?